MATRIX RELOADED: Doctors Try New Techniques To Regrow Human Tissue
By Ron Winslow,
Wall Street Journal
| 02. 12. 2007
Five soldiers at a military base in Texas are about to participate in a remarkable test to see if they can regrow portions of fingers they lost in the war in Iraq.
Doctors plan to treat them with a fine powder called extracellular matrix, harvested from pig bladders. The material, found in all animals, is the scaffolding that cells latch onto as they divide and grow into tissue and body parts. In the human body, it was long thought to be inert. But scientists have discovered that it appears to activate latent biological processes that spur healing and regenerate tissue.
Medical researchers have been making intriguing progress in the field of regenerative medicine. The pilot test in Texas shows how doctors are trying to apply their recent discoveries to a pressing challenge: helping thousands of Americans returning from Iraq to recover from wounds that would have killed soldiers a generation ago.
Scientists have long been enthralled by the ability of animals such as salamanders, starfish and deer to regrow body parts lost due to injury or other causes. Cut off...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...